UNSPSC 51333501: Clopimozide

This classification denotes a dopamine antagonist with the molecular formula C28H28ClF2N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7C6TA32SD2, chemically known as 5-chloro-1-(4-(4,4-bis(p-fluorophenyl)butyl)-4-piperidyl)-2-benzimidazolinone but generally known as clopimozide, which bears US NIH Compound Identifier 65449. European Medicines Agency schedules Clopimozide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06740MIG.

UNSPSC 51333501 Clopimozide is a Commodity code designating a specific pharmaceutical product, but recent state and local procurement activity tagged with this code does not reflect direct purchasing of clopimozide itself. Instead, the recent solicitations reveal that state and local governments are procuring naloxone and drug deactivation systems, generic multi-source pharmaceuticals with OTC products through cooperative purchasing networks, and exploring direct-to-manufacturer prescription fulfillment models. The issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving multiple states including Oregon). These solicitations show that pharmaceutical procurement under this taxonomy tier spans emergency-response medications, bulk generic drug supply agreements for government health programs, and pharmacy benefit program restructuring initiatives rather than single-molecule active pharmaceutical ingredients.

Activity appears concentrated in the South and Upper Midwest. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023 (note: date inconsistency in source); Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capability information for a direct-to-manufacturer prescription program with no formal award timeline; and the Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities in Minnesota, Oregon, and other member jurisdictions, with proposals due March 26, 2026. The code's recent activity does not align tightly with clopimozide procurement; state and local buyers appear to be using this code for broader pharmaceutical sourcing rather than this specific compound.